Multiple myeloma trials in Spain

In Spain 82 Also abroad 703

82 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Where
Ávila, Granada, Madrid, Málaga, Valencia, Vigo
Age
18 years and over
People
900 worldwide
Run by
Janssen-Cilag Ltd.
See details and how to joinNCT06285318
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Where
Badalona, Córdoba, Gijón, Jerez de la Frontera, Madrid, Málaga, Salamanca, Vitoria
Age
18 years and over
People
200 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07227311 · EU 2025-523117-28-00
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Pamplona, Salamanca, Santander, Sevilla, Terrassa, Toledo, Valencia
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Badalona, Barakaldo, Barcelona, Girona, Madrid, Málaga, Murcia, Salamanca, Terrassa, Valencia
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 1/2Taking people
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Where
Barcelona, Gijón, Madrid, Móstoles, Murcia, Palma, Pamplona, Valencia
Age
18 years and over
People
220 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00
Phase 1Taking people
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
Where
Sevilla
People
7 worldwide
Run by
USWM Ct LLC
See details and how to join2024-513033-21-00 · EU 2024-513033-21-00
Phase 3Taking people
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Where
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia
Age
18 years and over
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07764978
Phase 3Taking people
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
Where
Barcelona, Madrid, Pamplona, Salamanca, Santander, Valencia
Age
18 years and over
People
153 worldwide
Run by
AstraZeneca AB
See details and how to join2025-523285-25-00 · EU 2025-523285-25-00
Phase 3Not yet taking people in Spain
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Where
Madrid, Pamplona, Santander
Age
18 years and over
People
520 worldwide
Run by
AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00
Phase 2Taking people
Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
Where
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Sevilla
Age
18 years and over
People
20
Run by
Fundacion Pethema
See details and how to join2023-510560-12-00 · EU 2023-510560-12-00
Phase 2Taking people
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Where
Barcelona, Gijón, Granada, L'Hospitalet de Llobregat, Madrid, Majadahonda, Murcia, Terrassa
Age
18 years and over
People
116 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06140524 · EU 2023-505242-25-00
Phase 4Taking people
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Where
Barcelona, Madrid, Pamplona, Valencia
Age
18 years and over
People
80 worldwide
Run by
Pfizer
See details and how to joinNCT06057402 · EU 2023-505200-33-00
Phase 1/2Taking people
Phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Murcia, Salamanca, Santander, Sevilla, Valencia, Zaragoza
Age
18 years and over
People
62
Run by
Idp Discovery Pharma S.L.
See details and how to join2024-519194-19-00 · EU 2024-519194-19-00
Phase 3Taking people
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
Where
Albacete, Alcalá de Henares, Badalona, Barcelona, Bilbao, Burgos, Cáceres, Gijón, Girona, Granada, Guadalajara, Jerez de la Frontera, León, Lleida, Logroño, Lugo, Madrid, Málaga, Móstoles, Murcia, Ourense, Oviedo, Palma de Mallorca, Pamplona, Pontevedra, Pozuelo de Alarcón, Salamanca, San Cristóbal de La Laguna, San Sebastián, San Sebastián de los Reyes, Santa Cruz de Tenerife, Santander, Santiago de Compostela, Segovia, Seville, Tarragona, Terrassa, Toledo, Valencia, Vitoria-Gasteiz, Zaragoza
Age
18 years to 65 years
People
480
Run by
PETHEMA Foundation
See details and how to joinNCT05558319
Phase 1/2Taking people
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Where
Badalona, Barcelona, Madrid, Pamplona, Valencia
Age
18 years and over
People
250 worldwide
Run by
CellCentric Ltd.
See details and how to joinNCT04068597
No phaseTaking people
Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
Where
Madrid
Age
18 years and over
People
350
Run by
Infanta Leonor University Hospital
See details and how to joinNCT07609576
Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Badalona, Barcelona, Gijón, Madrid, Málaga, Murcia, Salamanca, Santander, Valladolid
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
Phase 2Taking people
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Where
Barcelona, Las Palmas De Gran Canaria, Murcia, Salamanca
Age
18 years and over
People
150 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT07107529 · EU 2024-520433-76-00
Phase 1Taking people
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Where
Badalona, Barcelona, Madrid, Pamplona, Salamanca
Age
18 years and over
People
200 worldwide
Run by
Ichnos Sciences SA
See details and how to joinNCT05862012 · EU 2023-507071-21-01
Phase 1Taking people
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
Where
Barcelona, Madrid
Age
18 years and over
People
87 worldwide
Run by
Sanofi
See details and how to joinNCT06630806
Phase 3Taking people
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Where
Badalona, Barcelona, Madrid, Santander, Valencia
Age
18 years and over
People
1,000 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00
Phase 1/2Taking people
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Where
Albacete, Barcelona, Cáceres, Las Palmas, Madrid, Oviedo, Salamanca, Santander, Santiago de Compostela, Valencia
Age
12 years and over
People
606 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555
Phase 1Taking people
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Where
Madrid, Pamplona, Salamanca
Age
18 years and over
People
187 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06153251 · EU 2023-506003-26-00
No phaseTaking people
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Where
Madrid, Palma
Age
18 years and over
People
75 worldwide
Run by
Takeda
See details and how to joinNCT05879757
No phaseTaking people
GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma
Where
Alcañiz, Almería, Ávila, Burgos, Girona, Granada, Huesca, Jaén, Lleida, Madrid, Málaga, Ourense, Palma de Mallorca, Ponferrada, Sabadell, Valdepeñas, Valencia, Valladolid, Vigo, Vitoria-Gasteiz
Age
18 years to 99 years
People
210
Run by
Fundación Española de Hematología y Hemoterapía
See details and how to joinNCT05992532